NCT04847453 2026-03-18
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
31 trialsNCT06169215 2026-03-18
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06948084 2026-03-18
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07463807 2026-03-18
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT03798678 2026-03-17
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04933539 2026-02-27
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02101944 2024-05-17
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01660997 2019-12-16
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01711528 2018-05-11
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00410605 2017-09-01
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023530 2016-02-18
Blood and Marrow Transplant Clinical Research Network
National Heart, Lung, and Blood Institute (NHLBI)
Phase NA Completed
NCT00522392 2015-06-26
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
National Cancer Institute (NCI)
Phase 3 Terminated
NCT01078441 2015-01-12
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00033332 2014-04-04
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00389701 2014-01-10
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00017602 2014-01-06
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00742404 2013-12-18
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003603 2013-09-20
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00028886 2013-09-17
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00416897 2013-08-26
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003493 2013-07-18
Combination Chemotherapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00003007 2013-06-26
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006232 2013-05-15
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00438841 2009-03-13
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown